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OBJECTIVES: Ambulatory protocol for the management of
patients with TIA has been shown to be as effective as the
standard inpatient protocol in terms of health outcomes. The
purpose of this study is to assess the avoided costs derived from
the progressive introduction of an ambulatory care strategy for
patients with TIA by using a neurosonological study at emer-
gency department instead of the standard protocol based on
inpatient care. METHODS: This is a retrospective analysis of the
costs of two treatments for patients with TIA treated in neuro-
logical emergencies of the University Hospital Virgen de las
Nieves (Granada, Spain) from January 2002 to July 2005. Costs
were evaluated from the hospital perspective, including direct
costs of the treatments. RESULTS: Unitary costs of ambulatory
and hospitalization care were 428.08€ and 2297.87€ respec-
tively. From January 2002 to July 2005, 338 patients with TIA
have been attended in the University Hospital Virgen de las
Nieves, of which 159 (47.04%) have been assigned to ambula-
tory treatment. The progressive introduction of the ambulatory
treatment in the period of study has avoided costs of 297,296€.
In terms of opportunity costs, these saving could fund the treat-
ment of 694 or 129 additional patients in the ambulatory and
inpatient treatments respectively. CONCLUSION: Treatments of
TIA are costly, mainly due to the length of the stay for such
procedures. The availability of the neurosonological study at
emergency departments followed by an ambulatory consultation
in a short time period allows a quick diagnostic and treatment of
patients arriving with TIA symptoms, avoiding a number of stays
by this cause and thus saving resources and reducing costs. The
effectiveness equivalence of both ambulatory and hospitalization
treatments and the much fewer costs of ambulatory care, support
the recommendation of the ambulatory strategy.
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OBJECTIVES: Juvenile myoclonic epilepsy (JME) is one of the
most common epilepsy syndromes accounting for approximately
7% of all cases of epilepsy. Choosing an appropriate antiepileptic
drug (AED) is essential for the proper management of JME
because of the possibility of exacerbation of seizures by some
AEDs and the adverse effect proﬁles of effective drugs. This study
aims to estimate the incremental budgetary impact of introducing
levetiracetam adjunctive therapy for JME patients in Scotland.
METHODS: A budget impact model was built to estimate the
additional costs or savings generated by the introduction of
levetiracetam adjunctive therapy for JME patients. The model
was designed from the Scottish NHS perspective for a 3-year time
horizon. Prevalence and incidence data of epilepsy were obtained
from published literature. Scottish population estimates were
based on mid-2005 estimates from the General Register Ofﬁce of
Scotland (2006). Levetiracetam adjunctive therapy was com-
pared with topiramate adjunctive therapy. As resources used
relating to general care, management of associated adverse events
and of seizures were assumed to be the same for both adjunctive
therapies, only drug acquisition costs were considered in this
analysis. RESULTS: It is estimated that there are 2841 current
cases and 142 new cases of JME each year. Based on levetirac-
etam market uptake, the number of patients with JME receiving
levetiracetam is expected to be 28, 71, and 128 over the next 3
years. The incremental cost of using levetiracetam compared to
topiramate adjunctive treatment is expected to be 5 per patient
per year, resulting in an incremental budget impact of 156 to
698 over the next three years. This increase is mainly due to the
increased market uptake of levetiracetam. CONCLUSION:
Introducing levetiracetam adjunctive therapy for JME patients is
predicted to have a limited impact on the Scottish NHS budget
over a 3-year time period.
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OBJECTIVES: To identify the budget impact of dopamine ago-
nists: piribedil (Pronoran) and ropinirol (Requip) in Parkinson
disease based on alternative reimbursement scenarios in Poland.
METHODS: Calculations were based on Polish data on dopam-
ine agonists sales for period 01.2006–03.2007 (IMS Poland). An
assumption about 50% of patients with newly diagnosed Parkin-
son disease treatment with dopamine agonists was established.
Estimates of the reimbursement costs when treatment of the
eligible population were done taking into consideration three
different scenarios: 1) Requip is reimbursed (6.68PLN per DDD)
but no public coverage for Pronoran; 2) both drugs are reim-
bursed but reimbursement for Requip (4.59PLN per DDD) is
limited by Pronoran (3.67PLN per DDD); and 3) both drugs are
reimbursed and reimbursement level per DDD is the same in case
of Pronoran and Requip (3.67PLN per DDD). Net budgetary
effects for public payer were calculated when scenario: 2 or 3 was
compared with scenario 1. All calculations were made for 2006
(1€ = 3.8PLN). RESULTS: Taking into account annual sales of
the drugs and assumed that scenario 1 is replaced by scenario 2
it occurred that total savings for public payer in Poland were:
3530000PLN–10611000PLN (€ 923000–2792000) per year. In
case of Pronoran and Requip were reimbursed and both had the
same reimbursement level (3.67PLN per DDD) total savings for
public payer in Poland would be: 4174000PLN–12522000PLN
(€ 1098000–3295000) annually. CONCLUSION: Pronoran
reimbursement in Poland lead to signiﬁcant savings for public
payer. The savings are especially high in case of the same reim-
bursement level per DDD for Pronoran and Requip.
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OBJECTIVES: To analyse the utilisation of drugs for treatment
of neurological disorder (ATC group: N01–N07) within Slovakia
between 1997 and 2006 and to asses the economic consequences
of the medications. METHODS: For 1997–2006, the data about
consumption of drugs for treatment of neurological disorder
were collected, in accordance with the Anatomic Therapeutic
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